moneyheap
BIO · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Bio-Rad Laboratories, Inc. Class A (BIO) stock moving?
Bio-Rad closed at $386.48 on Nov 10, up about 6% from $363.50 on Oct 22. The move follows Q3 results on Nov 4 that beat estimates: non-GAAP EPS of $2.65 versus $2.23 expected, and sales of $656.4M versus $649.95M. Currency-neutral sales grew 0.7%, with Clinical Diagnostics up 2.8% and Life Science down 2.4%. GAAP results were weaker, with an operating loss of $(49.7)M linked to restructuring and impairment items, although GAAP net income was $458.6M. Management affirmed FY2026 sales guidance of $2.506B-$2.596B, but the midpoint of $2.551B is slightly below the $2.588B consensus. RBC raised its target from $390 to $440 on Nov 5 and kept Outperform, about 14% above the Nov 10 close. The stock sold off to $369 on Nov 5 on 434K shares despite the raise, then rebounded. On Nov 9 it traded on 547K shares, set a new 30-day high of $394.73 and closed at $388.31 near the session high. Positives are the earnings beat, the analyst upgrade and improving price momentum. Risks are soft currency-neutral growth, Life Science weakness, the guidance midpoint below consensus, and GAAP losses.
News behind the analysis
- RBC Capital Markets Raises Price Target on Bio-Rad LaboratoriesRBC Capital Markets raised its price target on Bio-Rad from $390 to $440 and kept an Outperform rating.
- RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $440Benzinga reports the same RBC move, with the price target raised to $440 and the Outperform rating maintained.
- Bio-Rad Laboratories, Inc. Reports Third-Quarter 2026 Financial ResultsBio-Rad reported Q3 2026 adjusted EPS of $2.65 and revenue of $656.4 million for the quarter ended September 30, 2026.
- Bio-Rad Laboratories Affirms FY2026 Sales Guidance of $2.506B-$2.596B vs $2.588B EstBio-Rad reaffirmed its FY2026 sales guidance of $2.506B to $2.596B; the midpoint sits slightly below the $2.588B estimate.
- Bio-Rad Laboratories Q3 Adj. EPS $2.65 Beats $2.23 Estimate, Sales $656.400M Beat $649.950M EstimateAdjusted EPS of $2.65 beat the $2.23 estimate, and sales of $656.4M beat the $649.95M estimate.
- Bio-Rad Laboratories Q3 2026 Earnings Call TranscriptBio-Rad published the transcript of its Q3 2026 earnings call, which was held on Wednesday, November 4.
- Bio-Rad Laboratories, Inc. CFO to Participate in UBS Global Healthcare ConferenceCFO Roop K. Lakkaraju will take part in a fireside chat at the upcoming UBS Global Healthcare Conference.
About Bio-Rad Laboratories, Inc.Class A
Bio-Rad Laboratories, based in Hercules, California, makes lab instruments, reagents and test products for life science research and clinical diagnostics. It had about $2.6 billion in revenue in 2025. It is known for its droplet digital PCR (ddPCR) systems and its diagnostic quality-control and blood-typing products, and it also owns a large stake in the German lab supplier Sartorius.
How it makes money
Clinical Diagnostics brings in roughly 60% of sales. This segment sells quality controls, blood-typing, immunology and diabetes tests to hospital and clinical labs, and much of that revenue repeats as labs keep reordering supplies. Life Science brings in roughly 40%. It sells to universities, research institutes and biopharma companies, and its products include digital PCR and other PCR tools, protein-analysis and imaging gear, and process chromatography resins used to make biologic drugs. In Q3 2026, revenue was about $656 million: roughly $402 million from Diagnostics and $255 million from Life Science.
What usually moves BIO
- Academic and government research funding
- Biopharma spending and process chromatography demand
- Digital PCR instrument adoption
- Clinical lab test volumes and international exposure (e.g., Middle East disruption)
- Value of its Sartorius stake and currency moves